Equities Analysts Set Expectations for EHC Q3 Earnings

Encompass Health Corporation (NYSE:EHC) – Zacks Research upped their Q3 2025 EPS estimates for Encompass Health in a note issued to investors on Wednesday, October 22nd. Zacks Research analyst Team now anticipates that the company will post earnings of $1.18 per share for the quarter, up from their previous estimate of $1.17. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Encompass Health’s current full-year earnings is $4.80 per share. Zacks Research also issued estimates for Encompass Health’s Q4 2025 earnings at $1.28 EPS, FY2025 earnings at $5.22 EPS, Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.24 EPS, FY2026 earnings at $5.48 EPS, Q1 2027 earnings at $1.45 EPS, Q3 2027 earnings at $1.34 EPS and FY2027 earnings at $5.82 EPS.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Wednesday, March 16th. The company reported $0.93 earnings per share (EPS) for the quarter. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The business had revenue of $136.30 million for the quarter. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS.

Several other research firms have also issued reports on EHC. KeyCorp lifted their price target on shares of Encompass Health from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. UBS Group boosted their price objective on shares of Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, October 2nd. Truist Financial boosted their price objective on shares of Encompass Health from $135.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Weiss Ratings reissued a “buy (b+)” rating on shares of Encompass Health in a report on Wednesday, October 8th. Finally, Bank of America boosted their price objective on shares of Encompass Health from $145.00 to $160.00 and gave the company a “buy” rating in a report on Wednesday, September 10th. Two equities research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $139.86.

Encompass Health Price Performance

NYSE EHC opened at $126.22 on Thursday. The firm’s fifty day simple moving average is $123.98 and its two-hundred day simple moving average is $117.66. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.76. Encompass Health has a 12-month low of $87.85 and a 12-month high of $127.86. The firm has a market capitalization of $12.71 billion, a P/E ratio of 24.70, a P/E/G ratio of 2.18 and a beta of 0.93.

Institutional Investors Weigh In On Encompass Health

Several hedge funds have recently added to or reduced their stakes in EHC. Norges Bank purchased a new stake in Encompass Health in the second quarter valued at $139,536,000. Congress Asset Management Co. purchased a new stake in Encompass Health in the second quarter valued at $92,691,000. 8 Knots Management LLC purchased a new stake in Encompass Health in the second quarter valued at $78,644,000. Nuveen LLC purchased a new stake in Encompass Health in the first quarter valued at $50,665,000. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in Encompass Health by 25.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 2,080,918 shares of the company’s stock valued at $210,756,000 after purchasing an additional 424,691 shares during the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Encompass Health news, EVP Patrick William Tuer sold 1,020 shares of the company’s stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $123.59, for a total value of $126,061.80. Following the sale, the executive vice president directly owned 18,846 shares of the company’s stock, valued at approximately $2,329,177.14. This represents a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.00% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.